title: Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer.
abstract: In forthcoming multicentre studies on stereotactic body radiotherapy (SBRT) compliance with volume and dose prescriptions will be mandatory to avoid unnecessary heterogeneity bias. To evaluate compliance in a multicentre setting we used two cases from an ongoing phase II study of SBRT of T1-T2N0M0 inoperable NSCLC in a dummy run oriented on volumes and doses. Six Scandinavian centres participated. Each centre received CT-scans covering the whole lung volumes of two patients with instructions to follow the study protocol when outlining tumour and target volumes, prescribing doses and creating dose plans. Volumes and doses of the 12 dose plans were evaluated according to the study protocol. For the two patients the GTV volume range was 24 to 39 cm3 and 26 to 41 cm3, respectively. The PTV volume range was 90 to 116 cm3, and 112 to 155 cm3, respectively. For all plans the margin between CTV and PTV in all directions followed in detail the protocol. The prescribed dose was for all centres 45 Gy/3 fractions (isocentre dose about 66 Gy). The mean GTV doses ranged from 63 to 67 Gy and from 63 to 68 Gy, respectively. The minimum doses for GTV were between 50-64 Gy and between 55-65 Gy, respectively. The dose distribution was conformed to PTV for 10 of 12 plans and 2 of 12 plans from one centre had sub-optimal dose distribution. Most of the volume and dose parameters for the participating centres showed fully acceptable compliance with the study protocol.
authors.affiliation: Department of Oncology and Radiation Physics, Sahlgrenska University Hospital in Gothenburg, Sweden. emma.djarf@vgregion.se
authors.forename: Emma
authors.initials: E
authors.lastname: Djärv
authors.forename: Jan
authors.initials: J
authors.lastname: Nyman
authors.forename: Pia
authors.initials: P
authors.lastname: Baumann
authors.forename: Lars
authors.initials: L
authors.lastname: Ekberg
authors.forename: Morten
authors.initials: M
authors.lastname: Høyer
authors.forename: Ingmar
authors.initials: I
authors.lastname: Lax
authors.forename: Rolf
authors.initials: R
authors.lastname: Lewensohn
authors.forename: Nina
authors.initials: N
authors.lastname: Levin
authors.forename: Jo-Asmund
authors.initials: JA
authors.lastname: Lund
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Morhed
authors.forename: Susanne Rehn
authors.initials: SR
authors.lastname: Ericsson
authors.forename: Anders
authors.initials: A
authors.lastname: Traberg
authors.forename: Lena
authors.initials: L
authors.lastname: Wittgren
authors.forename: Karl-Axel
authors.initials: KA
authors.lastname: Johansson
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D017322:Clinical Trials, Phase II as Topic; D019983:Guideline Adherence / Q000458:organization & administration*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D011829:Radiation Dosage; D016634:Radiosurgery / Q000379:methods*; D011880:Radiotherapy Planning, Computer-Assisted; D047368:Tumor Burden